1,721,010 research outputs found
Role of non-cardiac comorbidities in heart failure across the ejection fraction spectrum : diagnosis, treatment and prognosis
No full textBackground. Heart failure (HF) represents a significant challenge due to its heterogeneous nature across the spectrum of ejection fraction (EF). This heterogeneity is in part characterized by a difference in distribution and prognostic role of comorbidities, both cardiac and non-cardiac, which impact patientŐs outcome and influence diagnostic and therapeutic approaches. Understanding patient profiles, where comorbidity has a key role, is crucial for optimizing HF trials and management strategies which involve also the effective management of non-cardiac comorbidities such as type 2 diabetes mellitus (T2DM), iron deficiency (ID), and chronic obstructive pulmonary disease (COPD).Aims. The primary aim of this thesis was to examine the role of non-cardiac comorbidities in patients with HF across the EF spectrum, in terms of epidemiology, treatment and clinical trial design aspects, by using data from the Swedish Heart Failure Registry (SwedeHF). Specific aims were to investigate:Ą Implementation of, independent predictors of, and outcomes associated with sodium-glucose contransporter-2 inhibitor (SGLT2i) use in patients with HF and T2DM (study I).Ą Epidemiology of ID in HF; and the implementation of, independent predictors of, and outcomes associated with ID testing and ferric carboxymaltose (FCM) use in patients with ID and HF (study II).Ą Real-world eligibility for sotagliflozin based on the SOLOIST-WHF selection criteria in patients stabilized after a HF hospitalization and with T2DM (study III).Ą Prevalence of, independent predictors of, and outcomes associated with COPD in patients with HF (study IV).Materials. All studies were based on data from SwedeHF, linked with additional national registries, with main statistical methods being logistic regression models for enhancing patient profiling, and Cox regression models for assessing independent associations between the exposures and the outcomes.Study I: Use of SGLT2i in HF and T2DM. Among 6,805 HF patients with T2DM use of SGLT2i increased gradually to ~12% in 2018. Patient characteristics independently associated with SGLT2i use included younger age, a follow-up in specialty care, ischemic heart disease (IHD), preserved renal function, and absence of anemia. SGLT2i use was associated with a 30% lower risk of cardiovascular (CV) death or HF hospitalization, regardless of EF, metformin use, and renal function.Study II: ID in HF. Of 21,496 HF patients enrolled in 2017-2018, ID testing was performed in 27%, revealing ID in 49% of tested patients. ID was associated with higher all-cause hospitalizations regardless of anemia. Only 19% of patients with ID received FCM. Independent predictors of ID testing and FCM use included anemia, higher New York Heart Association class, HF with reduced EF, and specialty care referral.Study III: Eligibility for Sotagliflozin. Applying SOLOIST-WHF trial selection criteria to 5,453 inpatients with T2DM and stabilized after a HF hospitalization, 27.2% were eligible whether all selection criteria were applied, and 62.8% whether only those more likely to impact its implementation in clinical practice were considered. Eligible patients had more severe HF and higher event rates, particularly CV and HF events.Study IV: COPD in HF. Among 97,904 HF patients enrolled in 2005-2021, COPD prevalence was 13%, highest in HFpEF (16%). COPD was linked with higher EF, female sex, smoking, peripheral artery disease, and lower education. COPD was independently associated with a 15% higher risk of CV death or HF hospitalization and worse outcomes regardless of EF. COPD patients had slightly lower use of guideline-directed HF treatments.Conclusions. The studies presented in this thesis indicate that SGLT2i use in patients with HF and T2DM increased over time between 2013 and 2018, particularly among younger patients with IHD and preserved renal function, and was associated with lower morbidity and mortality (study I). ID testing was underutilized and ID was frequent and associated with worse outcome, with many diagnosed patients not receiving recommended FCM treatment, indicating suboptimal adherence to HF guidelines (study II). Of HF patients with T2DM, a small proportion was eligible for sotagliflozin if applying trial selection criteria, questioning clinical trial findings generalizability to daily clinical practice (study III). COPD was prevalent in HF, and most in HFpEF, associated with more severe HF, higher comorbidity burden, slight HF undertreatment, and worse outcomes regardless of EF (study IV).List of scientific papersI. Peter Moritz Becher*, Benedikt Schrage*, Giulia Ferrannini, Lina Benson, Javed Butler, Juan Jesus Carrero, Francesco Cosentino, Ulf Dahlstršm, Linda Mellbin, Giuseppe M C Rosano, Gianfranco Sinagra, Davide Stolfo, Lars H Lund, Gianluigi Savarese. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. European Journal of Heart Failure. 2021, 23, 1012Đ1022. https://doi.org/10.1002/ejhf.2131 II. Peter Moritz Becher, Benedikt Schrage, Lina Benson, Marat Fudim, Carin Corovic Cabrera, Ulf Dahlstršm, Giuseppe M C Rosano, Ewa A Jankowska, Stefan D Anker, Lars H Lund, Gianluigi Savarese. Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. European Journal of Heart Failure. 2021, 23, 1844-1854. https://doi.org/10.1002/ejhf.2338 III. Peter, Moritz Becher*, Gianluigi Savarese*, Lina Benson, Ulf Dahlstršm, Patric Karlstršm, Peter G M Mol, Marco Metra, Deepak L Bhatt, Bertram Pitt, Lars H Lund. Eligibility for sotagliflozin in a real-world heart failure population-based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish Heart Failure Registry. European Heart Journal - Cardiovascular Pharmacotherapy. 2023, 9, 343-352. https://doi.org/10.1093/ehjcvp/pvad012 IV. Peter Moritz Becher, Felix Lindberg, Lina Benson, Camilla Hage, Ulf Dahlstršm, Stephan Rosenkranz, Francesco Cosentino, Giuseppe MC Rosano, Stefan Blankenberg, Paulus Kirchhof, Frieder Braunschweig, Lars H Lund, Gianluigi Savarese. Phenotyping patients with chronic obstructive pulmonary disease and heart failure: data from the Swedish Heart Failure Registry. [Submitted]</p
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Full text linkWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
koamabayili/VECTRON-author-checklist: VECTRON author checklist
No full textWe have done our best to complete the author checklist relating to the use of animals in the hut study. Note that the objective for the hut study was to evaluate the IRS treatment applications for residual efficacy against Anopheles mosquitoes, including the local An. coluzzii mosquito population. Cows were only used to attract mosquitoes into the huts and no tests were carried out directly on the cows. The author checklist is intended for use with studies where experiments are carried out on animals, which is why we have had such difficulty in completing this for the hut study, as many of the questions do not relate to how the cows were used
Author-wise bibliometric analysis based on entropy.
No full textAuthor-wise bibliometric analysis based on entropy.</p
Author Under Sail The Imagination of Jack London, 1893-1902
No full textIn Author Under Sail, Jay Williams offers the first complete literary biography of Jack London as a professional writer engaged in the labor of writing. It examines the authorial imagination in London's work, the use of imagination in both his fiction and nonfiction, and the ways he defined imagination in the creative process in his business dealings with his publishers, editors, and agents. In this first volume of a two-volume biography, Williams traverses the years 1893 to 1902, from London's "Story of a Typhoon" to The People of the Abyss. The Jack London who emerges in the pages of Author Under Sail is a writer whose partnership with publishers, most notably his productive alliance with George Brett of Macmillan, was one of the most formative in American literary history. London pioneered many author models during the heyday of realism and naturalism, blurring the boundaries of these popular genres by focusing on absorption and theatricality and the representation of the seen and unseen. London created an impassioned, sincere, and extremely personal realism unlike that of other American writers of the time. Author Under Sail is a literary tour de force that reveals the full range of London as writer, creative citizen, and entrepreneur at the same time it sheds light on the maverick side of machine-age literature.Intro -- Title Page -- Copyright Page -- Dedication -- Contents -- Acknowledgments -- Introduction -- 1. Spirit Truth -- 2. From Absorption to Theatricality and Back Again -- 3. "I Will Build a New Present" -- 4. Sons as Authors -- 5. Fathers as Publishers -- 6. The Daughter as Author -- 7. Lovers as Authors -- 8. At Sea with the Family -- 9. Yellow News, Yellow Stories -- 10. The Return Home -- Notes -- Bibliography -- Index -- About Jay WilliamsIn Author Under Sail, Jay Williams offers the first complete literary biography of Jack London as a professional writer engaged in the labor of writing. It examines the authorial imagination in London's work, the use of imagination in both his fiction and nonfiction, and the ways he defined imagination in the creative process in his business dealings with his publishers, editors, and agents. In this first volume of a two-volume biography, Williams traverses the years 1893 to 1902, from London's "Story of a Typhoon" to The People of the Abyss. The Jack London who emerges in the pages of Author Under Sail is a writer whose partnership with publishers, most notably his productive alliance with George Brett of Macmillan, was one of the most formative in American literary history. London pioneered many author models during the heyday of realism and naturalism, blurring the boundaries of these popular genres by focusing on absorption and theatricality and the representation of the seen and unseen. London created an impassioned, sincere, and extremely personal realism unlike that of other American writers of the time. Author Under Sail is a literary tour de force that reveals the full range of London as writer, creative citizen, and entrepreneur at the same time it sheds light on the maverick side of machine-age literature.Description based on publisher supplied metadata and other sources.Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, YYYY. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries
- …
